Filed with ASX · · 2 pages · English
TrivarX Limited has announced the engagement of Syntro Health to support the formulation of its Stabl-Im investigational product for clinical trials. This partnership marks a significant milestone in the preparations for the planned clinical feasibility study of Stabl-Im, which aims to evaluate its safety and effectiveness. Syntro Health will provide specialized pharmaceutical manufacturing services, leveraging its TGA-licensed facilities to advance the project. The planned study is set to begin patient enrollment in the first quarter of the following year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX ANNOUNCEMENT 22 October 2026 Syntro Health engaged to advance Stabl-Im clinical trial formulation • Australian pharmaceutical manufacturing specialist Syntro Health to undertake laboratory formulation activities for the Company’s Stabl-Im investigational product • Engagement represents a...
